Literature DB >> 21764784

Immuno-PET of cancer: a revival of antibody imaging.

Otto C Boerman, Wim J G Oyen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21764784     DOI： 10.2967/jnumed.111.089771

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  18 in total

Review 1.  New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions.

Authors:  Graham Smith; Laurence Carroll; Eric O Aboagye
Journal:  Mol Imaging Biol       Date:  2012-12       Impact factor: 3.488

2.  Multifunctional Desferrichrome Analogues as Versatile 89Zr(IV) Chelators for ImmunoPET Probe Development.

Authors:  Casey J Adams; Justin J Wilson; Eszter Boros
Journal:  Mol Pharm       Date:  2017-07-19       Impact factor: 4.939

3.  Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques.

Authors:  Philip J Santangelo; Kenneth A Rogers; Chiara Zurla; Emmeline L Blanchard; Sanjeev Gumber; Karen Strait; Fawn Connor-Stroud; David M Schuster; Praveen K Amancha; Jung Joo Hong; Siddappa N Byrareddy; James A Hoxie; Brani Vidakovic; Aftab A Ansari; Eric Hunter; Francois Villinger
Journal:  Nat Methods       Date:  2015-03-09       Impact factor: 28.547

Review 4.  Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging.

Authors:  Kenneth M Tichauer; Yu Wang; Brian W Pogue; Jonathan T C Liu
Journal:  Phys Med Biol       Date:  2015-07-02       Impact factor: 3.609

Review 5.  Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.

Authors:  Kelly E Henry; Gary A Ulaner; Jason S Lewis
Journal:  PET Clin       Date:  2017-07

Review 6.  Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging.

Authors:  Rocío García-Vázquez; Umberto Maria Battisti; Matthias M Herth
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-30

Review 7.  Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.

Authors:  Kelly E Henry; Gary A Ulaner; Jason S Lewis
Journal:  PET Clin       Date:  2018-07

Review 8.  Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy.

Authors:  James C Knight; Bart Cornelissen
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

9.  Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Authors:  Kristoff Muylle; Patrick Flamen; Danielle J Vugts; Thomas Guiot; Ghanem Ghanem; Nathalie Meuleman; Pierre Bourgeois; Bruno Vanderlinden; Guus A M S van Dongen; Hendrik Everaert; Mélanie Vaes; Dominique Bron
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-20       Impact factor: 9.236

10.  Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting.

Authors:  J P Tiernan; S L Perry; E T Verghese; N P West; S Yeluri; D G Jayne; T A Hughes
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.